BNO.AX - Bionomics Limited

ASX - ASX Delayed price. Currency in AUD
0.0190
0.0000 (0.00%)
At close: 03:14PM AEST
Stock chart is not supported by your current browser
Previous close0.0190
Open0.0200
Bid0.0190 x 2640300
Ask0.0210 x 16362900
Day's range0.0190 - 0.0210
52-week range0.0190 - 0.0740
Volume1,512,935
Avg. volume1,437,845
Market cap27.906M
Beta (5Y monthly)2.26
PE ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings date23 Aug 2023 - 28 Aug 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est23.00
  • GlobeNewswire

    Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

    ADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators for serious central nervous system (CNS) disorders with a high unmet medical need, today announced it will present data on BNC210 for the treatment of Social Anxiety Disorder (SAD) at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

  • GlobeNewswire

    Quarterly Activities and Cashflow Report

    ADELAIDE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 31 March 2023 (Quarter) and up to the date o

  • GlobeNewswire

    Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

    Topline results expected in Q3 2023ADELAIDE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel allosteric ion channel modulators for serious central nervous system (CNS) disorders with high unmet medical need, today announced that the Company has completed target enrollment of approximately 200 participants in its randomized, double-blind, placebo-controlled, multi-center P

  • GlobeNewswire

    Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

    Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challengeResults achieved statistical significance in post-hoc analysis of the full data set and in relevant subpopulations Favourable safety, tolerability and PK findings are consistent with a fast-acting non-sedating anxiolytic profileThe company is planning an End of Phase 2 (EoPh2) meeting to discuss BNC210’s late-stage SAD program 2H 2023 Webcast and conference call sch

  • Zacks

    Bears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' Now

    Bionomics Limited Unsponsored ADR (BNOX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

  • Simply Wall St.

    Bionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

    Bionomics ( ASX:BNO ) First Half 2023 Results Key Financial Results Net loss: AU$16.2m (loss widened by 24% from 1H...

  • GlobeNewswire

    Bionomics’ Half-Year Report

    ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented a transformational time for Bionomics in which the Company made great strides on multiple fronts, including progress on advancing the pipeline, raising capital, and implementing strategic corporate initiatives designed to create long-term shareholder value. The Company recently completed its Phase 2

  • Simply Wall St.

    Will Bionomics (ASX:BNO) Spend Its Cash Wisely?

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

  • GlobeNewswire

    Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

    BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to PlaceboBNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior ExperienceCompany is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into mid-2024 ADELAIDE, Australia, Dec. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (B

  • GlobeNewswire

    Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

    Experienced biotech executive to lead the next phase of growthADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has appointed Spyridon “Spyros” Papapetropoulos, M.D. as

  • GlobeNewswire

    Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

    ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders, today announced it will present data on the development of an oral tablet formulation of BNC210 for the treatment of Social Anxiety Disorder (SAD) and data on the pharmacometr

  • GlobeNewswire

    Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States

    ADELAIDE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced the closing of an underwritten public offering in the United States (the “Offering”) of 641,026 American Depositary Shar

  • GlobeNewswire

    Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States

    ADELAIDE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced the pricing of an underwritten follow-on offering in the United States (the “Offering”) of 641,026 American Depositary S

  • GlobeNewswire

    Bionomics Limited to Participate in Upcoming November Investor Conferences

    ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will participate in the following upcoming investor conferences in November: Credit Suisse 31st Annual Healthcare Conferen

  • GlobeNewswire

    Quarterly Activities Report for September 2022

    ADELAIDE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 30 September 2022 (Quarter) and up to the dat

  • GlobeNewswire

    Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million

    ADELAIDE, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$4,634,307.30 research and development (R&D) tax incentive refund relating to the financial year ended June 2022. The Australian Government R&D tax incentive encourages companies to engage in R&D benefiting Australia, by providing a tax offset of up to 43.5% (refundable) for eli

  • Simply Wall St.

    Bionomics (ASX:BNO) adds AU$20m to market cap in the past 7 days, though investors from five years ago are still down 84%

    Bionomics Limited ( ASX:BNO ) shareholders should be happy to see the share price up 29% in the last week. But spare a...

  • GlobeNewswire

    Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference

    ADELAIDE, Australia, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be participating in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in San Francisco on O

  • GlobeNewswire

    Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder

    BNC210 is a First-in-Class Candidate in Clinical Development for the Acute Treatment of Social Anxiety Disorder with FDA Fast Track DesignationADELAIDE, Australia, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, toda

  • Zacks

    Can Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect?

    The mean of analysts' price targets for Bionomics Limited Unsponsored ADR (BNOX) points to a 329.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • GlobeNewswire

    Bionomics to Participate in Upcoming September Investor Conferences

    ADELAIDE, Australia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will participate in the following upcoming investor conferences in September: Citi’s 17th Annual BioPharma Conference Taking

  • Zacks

    Does Bionomics Limited Unsponsored ADR (BNOX) Have the Potential to Rally 329% as Wall Street Analysts Expect?

    The consensus price target hints at a 328.6% upside potential for Bionomics Limited Unsponsored ADR (BNOX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • Simply Wall St.

    We're Keeping An Eye On Bionomics' (ASX:BNO) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • GlobeNewswire

    Bionomics reports Full Year Financial Results

    ADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, Nasdaq:BNOX), today announced its financial results for the 12 months ended 30 June 2022. Bionomics is a clinical stage biopharmaceutical company developing novel, allosteric, ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective Negative Allosteri

  • GlobeNewswire

    Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M

    ADELAIDE, Australia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ:BNOX), a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$2,085,453.17 research and development (R&D) tax incentive refund relating to the financial year ended June 2021. The Australian Government R&D tax incentive encourages companies to engage in R&D benefiting Australia, by providing a tax offset of up to 43.5% (refundable) for eligible R&D activities. Rel